Introduction {#Sec1}
============

Oxidative stress represents an imbalance between the production and degradation of reactive oxygen species (ROS), such as superoxide anion or hydrogen peroxide created by myeloperoxidase, nitric oxide synthase, NADPH oxidase, xanthine oxidase, and other oxidases \[[@CR1]•, [@CR2], [@CR3]•\]. Hyperlipidemia, inflammatory conditions, or endothelial injury can cause increased ROS production, which can modify fatty acids, lipoproteins, and amino acids, thereby generating oxidation-specific epitopes (OSE). The characterization of oxidation of low-density lipoprotein (OxLDL) is a classic example of the consequences of a pro-oxidant and proinflammatory environment, generating a variety of OSE, such as the well-described oxidized phospholipid (OxPL) and malondialdehyde (MDA) epitopes on LDL \[[@CR4], [@CR5]\]. These OSE are biologically active by upregulating adhesion molecules to attract monocytes into the vessel wall, can mediate proinflammatory responses in cytokines and upregulation of pro-inflammatory genes, mediate macrophage retention and apoptosis, and are cytotoxic. OSE are pro-atherogenic by mediating the unregulated uptake of OxLDL in macrophages through scavenger receptors and generating activated macrophage foam cells. Furthermore, OSE are potent immunogens and can activate T cells and B cells, resulting in the generation of autoantibodies directed to unique OSE that can be present on lipids and proteins such as on OxLDL, lipoprotein (a) \[Lp(a)\], within macrophage foam cells, on proteins in the extracellular matrix, and on the surface of apoptotic cells \[[@CR6]••\].

It is now widely accepted that atherosclerosis is a chronic inflammatory disease and does not simply result from the bland accumulation of lipids \[[@CR7]\]. The nature of the inflammatory response includes the interaction of antigens, such as OSE, and immune cells such as monocyte/macrophages, T cells, and B cells. OSE can be regarded as a major target of many innate pattern recognition receptors, which are preformed, germline-encoded receptors, and presumably the product of natural selection. These OSE are ubiquitous in atherosclerotic lesions and represent "danger signals," thus constituting a class of pathogen-associated molecular patterns, which have led to the natural selection of multiple innate pattern recognition receptors that target such epitopes. This includes both cellular pattern recognition receptors, such as scavenger receptors and toll-like receptors (TLRs) on macrophages, and soluble pattern recognition receptors, such as natural antibodies. The finding that natural antibodies secreted from OxLDL-specific B-cell lines bind to oxidation-specific epitopes, block uptake of OxLDL by macrophages, recognize apoptotic cells, and are deposited in atherosclerotic lesions suggested a new role of innate immunity and pathogen-associated molecular patterns (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR6]••\]. Fig. 1Oxidation-specific epitopes are a class of pathogen-associated molecular patterns (PAMPs) that are recognized by natural antibodies and other innate immune receptors. Physiological and pathological stress can lead to the generation of oxidation-specific epitopes (altered self) on membranes of lipoproteins as well as cells (self), which are subsequently recognized by natural antibodies, scavenger receptors, and other innate effector proteins via these motifs. In many, if not all, cases, molecular mimicry exists between oxidation-specific epitopes of self-antigens and epitopes of infectious pathogens. 4-HNE, 4-hydroxynonenal; AGE, advanced glycation end product; CRP, C-reactive protein; Lp(a), lipoprotein \[a\]; MDA, malondialdehyde; OxCL, oxidized cardiolipin; OxLDL, oxidized LDL; PC, phosphorylcholine; SAA, serum amyloid A. (*Reprinted with permission from* Hartvigsen et al. \[[@CR6]••\])

Taking advantage of the biological and immunological properties of OSE, we have generated, characterized, and evaluated murine and human monoclonal antibodies as imaging agents. In this review, we will describe imaging of atherosclerosis and macrophages using oxidation-specific antibodies.

Antibodies to Oxidation-Specific Epitopes {#Sec2}
=========================================

MDA2 {#Sec3}
----

MDA2 is a murine monoclonal IgG type antibody specific for MDA-lysine epitopes. It binds MDA-LDL, and other MDA-modified proteins, but not native LDL, high-density lipoprotein, or very low-density lipoprotein \[[@CR8]\]. MDA2 immunostains MDA-lysine epitopes in various stages of atherosclerotic lesions, particularly early fatty streaks in humans and intermediate lesions of mice and rabbits \[[@CR9], [@CR10]•, [@CR11]••\].

E06 {#Sec4}
---

E06 is a natural IgM autoantibody cloned from apolipoprotein E--deficient mice (apoE^−/−^) that binds to the phosphocholine (PC) head group of oxidized but not normal phospholipids \[[@CR12]\]. E06 binds to PC of oxidized phospholipids when it is exposed as a result of conformational changes induced by oxidative modification of polyunsaturated fatty acid at the sn-2 position of phospholipids. E06 blocks the uptake of OxLDL and apoptotic cells by macrophages \[[@CR13]\]. Interestingly, E06 is structurally and functionally identical to classic "natural" murine T15 anti-PC antibodies that are of B-1 cell origin and are reported to provide optimal protection from virulent pneumococcal infection \[[@CR14]\]. This suggests that T15/E06 evolved through natural selection from B-1 cells and their physiological role may be in immune defense and housekeeping roles against PC-containing organisms, clearance of PC-containing apoptotic cells, and protection against oxidation-dependent changes \[[@CR6]••, [@CR15]\].

IK17 {#Sec5}
----

IK17 is a human monoclonal IgG antibody fragment (used either as a Fab fragment or single chain Fv fragment for imaging purposes) binding to MDA-LDL and copper OxLDL \[[@CR16]\]. The exact chemical structure of the epitope it recognizes is not fully defined, but it appears to be an MDA-like epitope that is expressed during extensive oxidative modification. IK17 was isolated from a phage display library from a patient with coronary artery disease with high plasma autoantibody titers to MDA-LDL. IK17 also inhibits the uptake of OxLDL and apoptotic cells by macrophages. Because IK17 is a human autoantibody it has potential advantages in imaging over murine antibodies to OSE, including improved pharmacokinetics and reduced immunologic reactions \[[@CR16]\]. Figure [2](#Fig2){ref-type="fig"} displays the concepts of oxidation-specific epitopes as antigens and imaging targets and oxidation-specific antibodies as the targeting agents. Fig. 2The *left panel* displays an illustration of LDL that is modified by a variety of oxidation-specific epitopes, including phosphocholine-containing oxidized phospholipids (oxPC), malondialdehyde (MDA and 4-hydroxynonenal \[HNE\] epitopes). The *right panel* displays an illustration of an IgG antibody showing its various effector functions. MDA2, E06, and IK17 are well-characterized oxidation-specific antibodies

In a recent study in human vulnerable plaques, we demonstrated that OSE were absent in normal coronary arteries. Early lesions immunostained for all epitopes but the overall extent was minimal. However, as lesions progressed, the presence of apoB and MDA epitopes did not increase, whereas OxPL and IK17 epitopes increased proportionally, but to different extent, as plaques advanced and in parallel to macrophage immunostaining \[[@CR17]\]. OxPL and IK17 epitopes were strongest in late lesions in macrophage-rich areas, lipid pools, and the necrotic core. OxPL and IK17 epitopes were most specifically associated with unstable and ruptured plaques. Thus, human coronary atherosclerotic lesions manifest a differential expression of oxidation-specific epitopes as they progress. These data provide a scientific rationale for targeting particular oxidation-specific epitopes for biomarker, imaging, and therapeutic ("biotheranostic") applications in humans.

Imaging Studies {#Sec6}
===============

Radionuclide Imaging {#Sec7}
--------------------

Initial studies aimed at imaging OSE were focused on using radionuclide techniques in a variety of animal models, including LDLR^−/−^ and apoE^−/−^ mice, cholesterol-fed New Zealand white rabbits, and Watanabe heritable hyperlipidemic (WHHL) rabbits using radiolabeled MDA2 and IK17 antibodies. In a series of experimental studies \[[@CR9], [@CR10]•, [@CR11]••\], it was established that intravenously injected radiolabeled antibodies strongly and preferentially accumulate within lipid-rich, oxidation-rich atherosclerotic lesions, and particularly in areas of increased content of OSE in the extracellular space or on foam cells as documented by concurrent immunostaining. Autoradiography and Sudan-stained images of aortas obtained 24 h after intravenous injection of ^125^I-MDA2 into apoE^−/−^ mice and WHHL rabbits revealed areas of lipid staining that were nearly identical to the autoradiography signal generated by the accumulation of ^125^I-MDA2 in the atherosclerotic lesions (Fig. [3](#Fig3){ref-type="fig"}). The uptake of ^125^I-MDA2, evaluated as the percent of the injected dose, was highest in the aorta compared to all other organs and tissues examined. It was also demonstrated that the uptake of ^125^I-MDA2 in atherosclerotic lesions was proportional to the plaque burden measured by both the percent atherosclerotic lesion area and aortic weight \[[@CR9], [@CR10]•\]. Interestingly, in the WHHL rabbits, enhanced uptake of ^125^I-MDA2 was also noted in the spleen and liver, which are known sites of the accumulation of OxPL in humans with nonalcoholic steatohepatitis (NASH), suggesting that it may be possible to noninvasively image NASH with this approach \[[@CR18]\]. Furthermore, ^99m^Tc-MDA2 successfully noninvasively imaged lipid-rich, oxidation-rich plaques (Fig. [3](#Fig3){ref-type="fig"}). Similar qualitative in vivo uptake and autoradiography results were obtained with ^125^I-IK17 Fab in LDL^−/−^ mice, except for a more rapid plasma clearance due to the smaller size of the Fab fragment \[[@CR16]\]. Fig. 3En-face preparations of Sudan-stained aortas from an apoE^−/−^ mouse (**a**) and a Watanabe heritable hyperlipidemic (WHHL) rabbit (**b**) injected with ^125^I-MDA2. *Red color* (*left panels* in **a** and **b**) signifies the presence of neutral lipid within the atherosclerotic plaque stained with Sudan IV, and *black color* (*right panels* in **a** and **b**) in the corresponding autoradiograph signifies the presence of accumulated ^125^I-MDA2 reflecting the presence of MDA-lysine epitopes. Panel **C** shows the relationship of ^125^I-MDA2 uptake and plaque burden as measured by aortic weight. A similar relationship is present with percent atherosclerosis surface area. Panels **d** and **e** represent in vivo imaging of atherosclerotic WHHL (**d**) and nonatherosclerotic New Zealand white (**e**) rabbits with ^99m^Tc-MDA2. (*Reprinted with permission from* Tsimikas et al. \[[@CR9]\], \[[@CR10]•\])

Imaging of the Progression and Regression of Atherosclerosis {#Sec8}
------------------------------------------------------------

The ability to quantitatively image changes in any target in atherosclerotic lesions, in this case OSE in the vessel wall, would be an important feature of any noninvasive imaging technique. This property would allow physicians to not only detect disease but also to monitor disease longitudinally over time following dietary, pharmacologic, device, or other therapeutic interventions. We have successfully established that, in principle, oxidation-specific antibodies can perform this type of function. In a dietary regression study, LDLR^−/−^ mice were fed a high-cholesterol, high-fat diet for 6 months and either continued on this diet (progression group) or placed back on normal mouse chow (regression group) for an additional 6 months, and each group was then injected with ^125^I-MDA2. Uptake of ^125^I-MDA2 was markedly reduced in mouse lesions undergoing atherosclerosis regression and correlated very strongly with features of plaque stabilization, including reduced macrophage content and increased collagen and smooth muscle cell content (Fig. [4](#Fig4){ref-type="fig"}) \[[@CR10]•, [@CR11]••\]. In addition, in this study and another rabbit study, there was evidence obtained by immunostaining that OSE disappeared from the vessel wall following a low-fat diet *prior* to physical plaque regression, suggesting that this may be a very early mechanism of plaque stabilization \[[@CR19], [@CR20]\]. Fig. 4En face preparation of Sudan-stained mouse aortas (*left*) and corresponding autoradiographs (*right*) showing representative examples of intravenously injected ^125^I-MDA2 distribution in the progression (**a**) and regression (**b**) groups. *Arrowheads* depict Sudan-stained areas with diminished ^125^I-MDA2 uptake. Panels **c--j** represent examples of immunostained atherosclerotic lesions from LDLR^−/−^ mice from the progression (**c**, **e**, **g**, **i**) and regression (**d**, **f**, **h**, **j**) groups. Immunostaining was performed for OxLDL, macrophages, smooth muscle cells (SMCs), and collagen. OxLDL and SMCs appear *pink/purple*, macrophages *black*, and collagen *bright blue*. Scale bar = 50 μm. (*Reprinted with permission from* Torzewski et al. \[[@CR11]••\])

These data in atherosclerotic mouse models are consistent with human data on the composition change of human carotid plaques following treatment with pravastatin for 3 months, where immunocytochemical staining by NA59, an antibody binding to the OSE 4-hydroxynonenal (HNE), and its quantitative analysis revealed significantly less immunoreactivity for HNE epitopes in the pravastatin-treated group compared to the control group \[[@CR21]\]. These data suggest that both dietary and statin-induced lipid-lowering therapy are associated with changes in human carotid plaque composition that favor lesion stability and that these changes can be detected and imaged with oxidation-specific antibodies.

MRI Using Gadolinium Micelles Containing Oxidation-Specific Antibodies {#Sec9}
----------------------------------------------------------------------

One of the limitations discovered in using radionuclide techniques with this approach was the modest target-to-blood ratios, which were not mediated by diminished plaque uptake of the ^125^I or ^99m^Tc radiolabeled antibodies, but instead by the high blood background due to the slow clearance of the radiolabeled antibodies. For translation to clinical imaging, because of the relatively short radiolabel half-life of ^99m^Tc and the relatively long biological half-life of antibody clearance, an optimal window where the maximal antibody uptake and binding coinciding with the maximal photon flux of ^99m^Tc was not feasible. This resulted in ^99m^Tc images that were suboptimal for a quantitative assessment of OSE. Thus far, PET techniques have not been evaluated with this approach.

To overcome this challenge, a series of experiments were performed using an MRI approach where oxidation-specific antibodies were covalently attached to gadolinium (Gd)-containing micelles (\~50 gadolinium ions per micelle) \[[@CR22]••\]. In short, micelles were prepared using 1,2-distearoyl-sn-glycer-3-phosphoethanolamine-n-methoxy (polyethylene glycol-2000), Gd-DTPA-bis, and PEG-malamide-DSPE by dissolving in chloroform:methanol with rhodamine added as a fluorescent label (Fig. [5](#Fig5){ref-type="fig"}). MDA2-micelles, E06-micelles, and IK17-micelles were modified with S-acetylthioglycolic acid N-hydroxysuccinimide ester and then covalently linked to the surface of the gadolinium micelles. The hydrated diameter of the micelles was 14 to 22 nm and their r1 values at 60 MHz were approximately 10 s^−1^ \* mmol/L^−1^ (Table [1](#Tab1){ref-type="table"}). Fig. 5Schematic of S-acetyl thioglycolic acid N-hydroxysuccinimide ester (SATA) attachment to antibodies, micelle composition, and attachment of antibodies to micelles. **a**, Composition of the micelles. **b**, Modification of the antibodies with the SATA linker to facilitate attachment to the micelles via the maleimide moiety. (*Reprinted with permission from* Briley-Saebo et al. \[[@CR22]••\])Table 1Physical and chemical properties and pharmacokinetics of Gd micellesFormulationSize, *nm*r1, 60 MHz (s^−1^ mM^−1^)Blood half-life, *h*%ID in liver of apoE^−/−^ mice at 24 hapoE^−/−^ miceWild-type miceMDA2-micelles22 ± 29.314.3\*1.718 ± 4IK17-micelles16 ± 310.516.5\*1.818 ± 4E06-micelles16 ± 310.820.1\*1.732 ± 2IgG-micelles16 ± 410.41.41.318 ± 3Untargeted micelles14 ± 211.61.51.512 ± 3\**P* \< 0.001 compared to wild-type mice

MRI was performed at 9.4 Tesla over a 96-hour time interval after the administration of 0.075 mmol Gd/kg micelles. MDA2-micelles and IK17-micelles showed maximal arterial wall uptake at 72 h and E06-micelles at 96 h, manifested by 125% to 231% enhancement in MR signal compared to adjacent muscle in cholesterol-fed apoE^−/−^ mice. In vivo imaging revealed significant signal enhancement with all targeted micelles, compared to untargeted micelles or micelles tagged with a nonspecific antibody (Fig. [6](#Fig6){ref-type="fig"}). No significant enhancement was observed after administration of either untargeted micelles or IgG micelles or of any micelles in wild-type mice. When excess free MDA2 was pre-injected, the plaque enhancement of MDA2 micelles was significantly reduced to a level comparable to that of untargeted micelles, confirming a specific targeting mechanism. Confocal microscopy confirmed the association of the MDA2 micelles and E06 micelles within the arterial vessel wall of apoE^−/−^ mice and colocalization of rhodamine of micelles with markers of macrophages showing uptake of micelles by macrophages (Fig. [7](#Fig7){ref-type="fig"}). Fig. 6Representative abdominal aorta (*arrows*) enhancement in apoE^−/−^ mice as a function of time following injection of 0.075 mmol Gd/Kg of micelles. The vessel to the *left* of the aorta is the inferior vena cava (IVC). The *bright white* areas at the abdominal aorta represent magnetic resonance enhancement of atherosclerotic plaque due to accumulation of antibody-tagged Gd micelles. Although arterial flow was saturated to allow for delineation of the arterial wall, some enhancement in the IVC may be observed due to flow artifacts. (*Reprinted with permission from* Briley-Saebo et al. \[[@CR22]••\])Fig. 7Confocal microscopy (63×) of apoE^−/−^ mouse aortic atherosclerotic plaque following the administration of MDA2-micelles and E06-micelles demonstrating nuclei (*blue*), macrophages (*green*), and micelles (*red*). The *lower panels* represent an atherosclerotic plaque from an apoE^−/−^ mouse not injected with micelles and stained with DAPI, showing the absence of significant autofluorescence (40×). (*Reprinted with permission from* Briley-Saebo et al. \[[@CR22]••\])

The uptake of targeted micelles within macrophages suggested the possibility of extracellular interactions of OxLDL with the targeted micelles. To ascertain this, we incubated macrophages that were pre-exposed to MDA-LDL with MDA2-micellles that were also pre-incubated with MDA-LDL and measured uptake by macrophages by confocal microscopy and quantitatively by ICP-MS studies (Fig. [8](#Fig8){ref-type="fig"}). The qualitative results indicate that when micelles were pre-exposed to MDA-LDL there was limited association of micelles with macrophages (column 1). When the macrophages were pre-exposed to MDA-LDL but the micelles were not there was association of MDA2-micelles and IK17-micelles with macrophages (column 2). When the MDA2-micelles and IK17-micelles were pre-incubated with MDA-LDL but the macrophages were not, there was even greater association of MDA2-micelles and IK17-micelles with macrophages (column 3). Finally, when both macrophages and micelles were pre-exposed to MDA-LDL, the highest association of MDA2-micelles and IK17-micelles with macrophages was noted (column 4). In contrast, minimal association of IgG-micelles or untargeted micelles was noted in any condition. This strongly suggests the mechanism that the entry of micelles within macrophage occurs on activated macrophages when the antibody-micelles interact with extracellular OxLDL and the entire particle is taken up within the macrophage. Studies are underway to assess the role of macrophage scavenger receptors or other uptake pathways, such as macropinocytosis, in the uptake of these targeted micelles. Fig. 8Confocal microscopy (63×) showing the association of micelles with macrophages in in vitro experiments. Macrophages and micelles were either exposed (+) or not exposed (--) to MDA-LDL prior to mixing together in cell culture. *Red* (rhodamine) represents the presence of micelles and *blue* (DAPI) macrophage nuclei. The *numbers under each panel* represent gadolinium content measured by inductively coupled plasma mass spectrometry (ICP-MS) normalized to total cell number. (*Reprinted with permission from* Briley-Saebo et al. \[[@CR22]••\])

MRI Using Iron Oxide Particles {#Sec10}
------------------------------

One disadvantage of using gadolinium-based MRI contrast agents is the potential for nephrogenic systemic fibrosis in renally impaired patients following injection of clinically available low-molecular-weight Gd chelates \[[@CR23]\]. Gd is known to come off its chelate at low (2%--3%) but measurable rates, and free Gd can be toxic to cells and induce apoptosis \[[@CR24]\]. Gd also has lower relaxivity compared to iron oxide nanoparticles. To circumvent this issue, we have recently explored the use of biocompatible iron oxide nanoparticles containing oxidation-specific antibodies to target them to atherosclerotic lesions, and specifically to macrophages. Prior studies with dextran-coated ultrasmall iron oxide particles (USPIOs) have passively targeted intraplaque macrophages \[[@CR25]\]. These USPIOs are desirable from a safety point of view, since cells associated with the reticuloendothelial system are able to safely eliminate iron \[[@CR26]\]. However, this passive targeting strategy may be suboptimal since these materials require slow infusion and long time-intervals between administration and MRI (\>24 h) \[[@CR27]\].

We therefore hypothesized that pegylated, lipid-coated iron oxide particles (without dextran) targeted to oxidation-specific epitopes may increase the clinical utility of the iron oxide platform for MRI of vulnerable atherosclerotic plaques. Lipid-coated ultra-small superparamagnetic iron particles (LUSPIO, \<20 nm) and superparamagnetic iron particles (LSPIO, \<40 nm) were conjugated with antibodies targeted to either MDA-lysine or oxidized phospholipid epitopes (Fig. [9](#Fig9){ref-type="fig"}). All formulations were characterized and their in vivo efficacy evaluated in apoE^−/−^ mice 24 h after bolus administration of a 3.9 mg Fe/kg dose using MRI (Table [2](#Tab2){ref-type="table"}) \[[@CR28]••\]. Fig. 9Schematic diagram of the lipid-coated iron oxide particles. The lipid-coated LUSPIOs were prepared by first synthesizing the mono-crystalline and mono-disperse iron core. PEG-DSPE, PEG-malamide-DSPE, and liss rhodamine are added at a ratio of 17.3 mg:1.3 mg:0.12 mg per milligram iron. Antibodies (0.35 mg/mg Fe) were attached to the LUSPIO and LSPIO surface via S-acetyl thioglycolic acid N-hydroxysuccinimide ester modification. (*Reprinted with permission from* Briley-Saebo et al. \[[@CR28]••\])Table 2Physical and chemical properties of lipid-coated ultra-small superparamagnetic iron particles (LUSPIO) and superparamagnetic iron particles (LSPIO)FormulationSize, *nm*r1, *s*^*−1*^  *mM*^*−1*^r2, *s*^*−1*^  *mM*^*−1*^Blood half-life apoE^−/−^, *h*Blood half-life WT, *h*%ID in liver (24 hrs p.i)Untargeted LUSPIO10 ± 314 ± 135 ± 21.521.4125Untargeted LSPIO35 ± 512 ± 1103 ± 41.021.0135MDA2 LUSPIO14 ± 313 ± 137 ± 29.011.5531MDA2 LSPIO38 ± 411 ± 1117 ± 57.281.1237IK17 LUSPIO12 ± 214 ± 135 ± 29.1231IK17 LSPIO36 ± 410 ± 1106 ± 57.3034E06 LUSPIO16 ± 412 ± 138 ± 29.3230E06 LSPIO39 ± 511 ± 1119 ± 67.4235All sizes are based upon the weighted number averages. The relaxivities shown were obtained in buffer at 60 MHz and 40°C. All blood half-lives and percent injected dose (%ID) in the liver were obtained in apoE^−/−^ or wild-type (WT) mice after injection of a 3.9-mg Fe/Kg dose

All MRI was performed at 9.4 Tesla using an 89-mm bore system operating at a proton frequency of 400 MHz (Bruker Instruments, Billerica, MA) prior to and 24 hours after the administration of a 3.9-mg Fe/Kg dose. In order to obtain in vivo R2\* maps, multiple echo GRE sequences with the following pulse sequence parameters were applied: TR = 29.1 ms, TE = 5.1 ms to 10 ms (*n* = 5), flip angle = 30°, number of signal averages (NEX) = 6, in-plane resolution = 0.098 mm^2^, and 100% z-rephasing gradient. Twenty slices were acquired from the level of the renal arteries to the iliac bifurcation. R2\*-maps were generated for matched pre and post images on a pixel-by-pixel basis using a custom Matlab program (The Mathworks, R2007b). The signal intensity associated with each pixel was normalized to the standard deviation of adjacent noise (placed above the spine of the mouse) prior to linear fitting of the signal-to-noise ratio versus echo time (TE). R2\* values were then obtained using regions of interest drawn on the arterial wall on slices (*n* \> 5) exhibiting either R2\* modulation post contrast or arterial wall thickening, indicative of plaque deposition. The relative percent changes in the R2\* values were determined as*% change* = *((R2\*post-R2\*pre)/R2\*post)\*100*.

Immediately following GRE acquisition, a GRASP sequence was applied using 50% of the z-rephasing gradient. GRASP is extremely useful when trying to determine if MR signal loss is due to iron oxide deposition or other endogenous artifacts (motion, partial voluming, and perivascular effects) that may also promote signal loss. GRASP cannot be used alone, however, since this sequence does not provide adequate anatomic information. In similarity to GRE sequences, GRASP signal may be observed in lymphatic tissue that may also sequester the iron oxide particles. However, this sequence is extremely useful to differentiate between iron oxide deposition and artifacts that are often present when imaging the arterial wall. Blooming artifacts cause the GRE images to sometimes show uniform signal loss while the GRASP images show focal, nonuniform enhancement. Phantom studies have indicated that GRASP sequence is less susceptible to blooming artifacts since very localized field inhomogeneities are required to produce strong GRASP signal. If the iron oxide particles are uniformly distributed or if the field distribution is large, then the GRASP signal is reduced since the local susceptibility differences cannot be matched.

In vivo imaging data were correlated with the presence of oxidation-specific epitopes using immunohistochemistry. MRI of atherosclerotic lesions, as manifested by signal loss, was observed following administration of targeted LUSPIOs (Fig. [10](#Fig10){ref-type="fig"}). In vivo competitive inhibition studies showed a 74.9% (*P* = 0.0002) reduction in R2\* for mice administered free MDA2 at the time of MDA2-labeled LUSPIO micelle injection, again implying a specific targeting mechanism. Limited signal attenuation was observed for untargeted LUSPIOs. Additionally, no significant arterial wall uptake was observed for targeted or untargeted LSPIOs due to their limited ability to penetrate the vessel wall. Immunohistochemistry of aortas of apoE^−/−^ mice administered the MDA2-labeled LUSPIO showed strong correlation between iron oxide (Perls' staining) and MDA-lysine epitope deposition (Fig. [11](#Fig11){ref-type="fig"}). Limited LUSPIO and MDA-lysine was observed in age-matched wild-type mice. Additionally, confocal microscopy confirmed the uptake of the oxidation-specific targeted LUSPIOs (rhodamine labeled) within atherosclerotic lesions and specifically within intraplaque macrophages/foam cells (anti-CD68 labeled) 24 hours post-injection. Rhodamine-labeled targeted LUSPIOs were not observed in the extracellular matrix. These results are consistent with the findings reported for MDA2-Gd micelles \[[@CR22]••\]. Additionally, strong co-localization between MDA epitopes and Perls' Prussian blue staining was observed, thereby confirming the presence of the targeted LUSPIOs in macrophages/foam cells enriched in oxidation-specific epitopes. Fig. 10Representative in vivo LUSPIO MRIs obtained prior to (pre) and 24 h after administration of a 3.9-mg Fe/Kg dose in apoE^−/−^ mice. The *yellow arrows* indicate the position of the lumen associated with the abdominal aorta. All GRE images shown were obtained using an echo time of 7 ms. Corresponding white marker GRASP images are also shown. For the competitive inhibition results, apoE^−/−^ mice were administered free excess MDA2 antibody at the time of MDA2-labeled LUSPIO injection. Matched histology sections show iron deposition (*blue*) within foam cells associated with the arterial wall. Relative percent changes in the R2\* values associated with the arterial wall following administration of the LUSPIO formulations are also shown (*bottom panel*). The error bars reflect the standard deviation associated with mean value obtained for mice receiving untargeted LUSPIOs and *n* = 6 mice receiving MDA2 or E06-labeled LUSPIOs. (*Reprinted with permission from* Briley-Saebo et al. \[[@CR28]••\])Fig. 11Immunohistochemistry (*top panel*) and confocal microscopy (*bottom panel*) of MDA2-labeled LUSPIOs in the arterial wall of apoE^−/−^ and wild-type mice. The arterial wall was stained for MDA-lysine (MDA3 staining), macrophages (MAC3), and iron oxide (Perl's) deposition. Confocal microscopy was using a multichannel laser so that co-localization between the cell nuclei (*blue*), macrophages (*green*), and MDA2-labeled LUSPIOs (*red*) could be performed. (*Reprinted with permission from* Briley-Saebo et al. \[[@CR28]••\])

These pegylated nanoparticles do not appear to be selectively taken up by macrophages unless they also contain an oxidation-specific antibody. In this way, they appear to selectively accumulate primarily within lipid-rich macrophage foam cells, perhaps due to binding extracellular OxLDL at these sites or to OxLDL bound on macrophage scavenger receptors that mediate particle uptake.

Conclusions {#Sec11}
===========

These sets of studies demonstrate that it is feasible to noninvasively image and quantitate oxidation-specific epitopes associated with atherosclerosis with both radionuclide and MRI techniques, particularly with biocompatible iron oxide nanoparticles that specifically target macrophages. The OSE targets are biologically validated as being strong markers of the presence and progression of atherosclerosis. The antibody-targeting agents appear to not only detect plaque burden, but importantly plaque composition, particularly plaque enriched in oxidized lipids and activated macrophages. Future studies will focus on translating these observations to human applications using human antibody fragments, such as single chain IK17, which have particular appeal for detecting advanced OSE in human vulnerable and ruptured plaques. The ability to detect and quantify OSE in humans will allow detection of high-risk plaques and provide the tools to allow surveillance following a variety of therapeutic interventions. This approach will have particular appeal initially in the carotid and peripheral circulation and, with advances in imaging techniques, possibly in coronary arteries as well.
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